These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 10953214)

  • 1. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate.
    Solomon GE
    Neurology; 2000 Aug; 55(4):606. PubMed ID: 10953214
    [No Abstract]   [Full Text] [Related]  

  • 2. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate.
    Hamer HM; Knake S; Schomburg U; Rosenow F
    Neurology; 2000 Jan; 54(1):230-2. PubMed ID: 10636156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two cases of valproate-induced hyperammonemic encephalopathy without hepatic failure.
    Panda S; Radhakrishnan K
    J Assoc Physicians India; 2004 Sep; 52():746-8. PubMed ID: 15839456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug induced encephalopathy in six epileptic patients: topiramate? valproate? or both?
    Latour P; Biraben A; Polard E; Bentué-Ferrer D; Beauplet A; Tribut O; Allain H
    Hum Psychopharmacol; 2004 Apr; 19(3):193-203. PubMed ID: 15079854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topiramate-valproate-induced hyperammonemic encephalopathy syndrome: case report.
    Cheung E; Wong V; Fung CW
    J Child Neurol; 2005 Feb; 20(2):157-60. PubMed ID: 15794187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperammonemic encephalopathy related to valproate, phenobarbital, and topiramate synergism.
    Gomez-Ibañez A; Urrestarazu-Bolumburu E; Viteri-Torres C
    Epilepsy Behav; 2011 Aug; 21(4):480-2. PubMed ID: 21700501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproate-induced hyperammonemic encephalopathy and normal liver functions: possible synergism with topiramate.
    Deutsch SI; Burket JA; Rosse RB
    Clin Neuropharmacol; 2009; 32(6):350-2. PubMed ID: 19952878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Report of three cases of hyperammonaemic encephalopathy associated with valproic acid due to possible synergism with phenobarbital and topiramate].
    Cano-Zuleta A; Hernández-Ortíz OH; González-González CA; Amariles P
    Farm Hosp; 2012; 36(5):441-2. PubMed ID: 22266198
    [No Abstract]   [Full Text] [Related]  

  • 9. [Valproate-induced hyperammonemic encephalopathy in a neonate: treatment with carglumic acid].
    Fernández Colomer B; Rekarte García S; García López JE; Pérez González C; Montes Granda M; Coto Cotallo GD
    An Pediatr (Barc); 2014 Oct; 81(4):251-5. PubMed ID: 24315420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patient.
    Hofer A; Fleischhacker WW; Hummer M
    J Clin Psychiatry; 2003 Oct; 64(10):1267-8. PubMed ID: 14658980
    [No Abstract]   [Full Text] [Related]  

  • 11. Encephalopathy in an infant with infantile spasms: possible role of valproate toxicity.
    Sivathanu S; Sampath S; Veerasamy M; Sunderkumar S
    BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24810446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Valproate-induced hyperammonemic encephalopathy].
    Granel B; Gavaret M; Le Baut X; Sautereau N; Rodriguez D; Rossi P; Bagnères D; Demoux AL; Francès Y
    Rev Med Interne; 2011 Jun; 32(6):e72-5. PubMed ID: 20633966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive topiramate enhances the risk of hypothermia associated with valproic acid therapy.
    Knudsen JF; Sokol GH; Flowers CM
    J Clin Pharm Ther; 2008 Oct; 33(5):513-9. PubMed ID: 18834366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
    Yamada H; Shishido T; Mukai T; Araki M; Naka H; Tokinobu H
    Rinsho Shinkeigaku; 2019 May; 59(5):258-263. PubMed ID: 31061301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valproate Induced Hyperammonemic Encephalopathy.
    Qayyum W; Yousafzai ZA; Iqbal MS; Khan S; Amin QK; Shafiqs I
    J Ayub Med Coll Abbottabad; 2022; 34(Suppl 1)(4):S1038-S1039. PubMed ID: 36550671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adding topiramate to valproate therapy may cause reversible hepatic failure.
    Bumb A; Diederich N; Beyenburg S
    Epileptic Disord; 2003 Sep; 5(3):157-9. PubMed ID: 14684351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproate induced hyperammonemic encephalopathy successfully treated with levocarnitine.
    Rigamonti A; Lauria G; Grimod G; Bianchi G; Salmaggi A
    J Clin Neurosci; 2014 Apr; 21(4):690-1. PubMed ID: 24119342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topiramate or valproate in patients with juvenile myoclonic epilepsy: a randomized open-label comparison.
    Levisohn PM; Holland KD
    Epilepsy Behav; 2007 Jun; 10(4):547-52. PubMed ID: 17482520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topiramate increases the risk of valproic acid-induced encephalopathy.
    Noh Y; Kim DW; Chu K; Lee ST; Jung KH; Moon HJ; Lee SK
    Epilepsia; 2013 Jan; 54(1):e1-4. PubMed ID: 22691153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lamotrigine might potentiate valproic acid-induced hyperammonemic encephalopathy.
    Fan CC; Huang MC; Liu HC
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Oct; 32(7):1747-8. PubMed ID: 18602440
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.